Samsung Biologics recognized as a global leader in water security
Company receives the highest Water Security rating in two years into participation Recognized for exceptional leadership in environmental stewardship INCHEON, South Korea, Dec. 11, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading...
Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 24, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions
BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest accelerated protein and antibody...
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a...
Samsung Biologics completes spin-off to strengthen its focus as a pure-play CDMO
Spin-off finalized within five months following board resolution Proposal approved in shareholders' meeting with 99.9% support Company to reaffirm its identity as a pure-play CDMO INCHEON, South Korea, Nov. 3, 2025 /PRNewswire/ -- Samsung Biologics...
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnership to Strengthen Global ADC CDMO Capabilities
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload...
Samsung Biologics reports third quarter 2025 financial results
Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion Recorded Q3'25 consolidated operating profit of KRW 728.8 billion Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships INCHEON, South Korea,...
Largest Milestone Payment Secured: Biokin, a Rising Chinese Pharmaceutical MNC
BEIJING, Oct. 22, 2025 /PRNewswire/ -- In October 2025, a partnership between Biokin—a rising star in China's innovative pharmaceutical sector—and global pharmaceutical leader BMS triggered a $250 million milestone payment. This is believed to be...
Samsung Biologics reports first quarter 2025 financial results
Recorded Q1'25 consolidated revenue of KRW 1.3 trillion Recorded Q1'25 consolidated operating profit of KRW 486.7 billion Company expected to maintain steady growth momentum in 2025 driven by enhanced operational efficiency and diverse service...
Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting
SAN FRANCISCO and SUZHOU, China, March 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...